表紙:注意欠陥多動性障害治療薬の世界市場:2021年~2027年
市場調査レポート
商品コード
1064773

注意欠陥多動性障害治療薬の世界市場:2021年~2027年

Attention Deficit Hyperactivity Disorder Drug Market 2021-2027

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 121 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
注意欠陥多動性障害治療薬の世界市場:2021年~2027年
出版日: 2022年02月01日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文 121 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の注意欠陥多動性障害治療薬の市場規模は、予測期間中に大幅なCAGRで拡大すると予測されています。新生児の早産児数の増加が、同市場の成長に寄与しています。メリーランド大学医療センター(UMMC)によると、この病気は現在、早産児の20%が罹患しています。世界中の政府は、注意欠陥多動性障害(ADHD)を含む数多くの精神障害に苦しむ人々の増加に注目しています。このような疾病の治療に対する政府の関心は、世界市場をさらに牽引するものと思われます。

当レポートでは、世界の注意欠陥多動性障害治療薬市場について調査し、市場の概要とともに、薬剤タイプ別、年齢群別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 市場の決定要因

  • 促進要因
  • 抑制要因
  • 市場の機会

第4章 市場セグメンテーション

  • 世界の注意欠陥多動性障害治療薬市場、薬剤タイプ別
    • 刺激剤
    • 非刺激剤
  • 世界の注意欠陥多動性障害治療薬市場、年齢群別
    • 子供
    • 大人
  • 世界の注意欠陥多動性障害治療薬市場、流通チャネル別
    • 院内薬局
    • 小売薬局
    • Eコマース

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • その他
  • その他の地域

第6章 企業プロファイル

  • Eli Lily & Company
  • Johnson & Johnson Services, LLC
  • Lupin Ltd.
  • Mallinckrodt
  • NEOS Therapeutics Inc.
  • Novartis AG
  • Pfizer Inc.
  • Prude Pharma L.P.
  • Shire
図表

LIST OF TABLES

  • 1. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 2. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER STIMULANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER NON-STIMULANTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2020-2027 ($ MILLION)
  • 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG FOR CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG FOR ADULTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG FOR HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG FOR RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG FOR E-COMMERCE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 12. NORTH AMERICAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 13. NORTH AMERICAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 14. NORTH AMERICAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2020-2027 ($ MILLION)
  • 15. NORTH AMERICAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 16. EUROPEAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 17. EUROPEAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 18. EUROPEAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2020-2027 ($ MILLION)
  • 19. EUROPEAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 20. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 21. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 22. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2020-2027 ($ MILLION)
  • 23. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 24. REST OF THE WORLD ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 25. REST OF THE WORLD ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2020-2027 ($ MILLION)
  • 26. REST OF THE WORLD ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SHARE BY DRUG TYPE, 2020 VS 2027 (%)
  • 2. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SHARE BY AGE GROUP, 2020 VS 2027 (%)
  • 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SHARE BY DISTRIBUTION CHANNEL, 2020 VS 2027 (%)
  • 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 5. US ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 6. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 7. UK ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 8. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 9. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 10. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 11. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 12. REST OF EUROPE ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 13. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 14. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 15. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 16. REST OF ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
  • 17. REST OF THE WORLD ATTENTION DEFICIT HYPERACTIVITY DISORDER DRUG MARKET SIZE, 2020-2027 ($ MILLION)
目次
Product Code: OMR2024267

Global Attention deficit hyperactivity disorder drug market Size, Share & Trends Analysis Report By Drug Type (Stimulants, Non-stimulants), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, e-Commerce) by Age Group (Children and Adults), and Forecast (2020-2026)

The global attention deficit hyperactivity disorder drug market is anticipated to grow at a considerable CAGR during the forecast period. The increase in the number of pre-term deliveries of newborns is contributing the growth of the global attention deficit hyperactivity disorder drug market. According to the University of Maryland Medical Center (UMMC), this disease affects 20% of prematurely born babies currently. Governments across the globe are paying attention to the growing number of people suffering from a number of psychological disorders, including attention deficit hyperactivity disorder (ADHD). This focus of government towards treatment of such disease is further likely to drive the global market.

The global attention deficit hyperactivity disorder drug market is segmented based on drug type, distribution channel, and age group. Based on drug type, the attention deficit hyperactivity disorder drug market is segmented into stimulants and non- stimulants. Based on distribution channel, the attention deficit hyperactivity disorder drug market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. Based on age group, the attention deficit hyperactivity disorder drug market is segmented into children and adults.

Geographically, the global attention deficit hyperactivity disorder drug market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World. Some of the companies operating in the global attention deficit hyperactivity disorder drug market include Pfizer Inc., Eli Lilly and Company., Novartis AG., GlaxoSmithKline PLC., Mallinckrodt Pharmaceuticals., Hisamitsu Pharmaceutical Co., Inc., and Johnson & Johnson., among others.

Market Segmentation

1. Global Attention Deficit Hyperactivity Disorder Drug Market Research and Analysis by Drug Type

2. Global Attention Deficit Hyperactivity Disorder Drug Market Research and Analysis by Age Group

3. Global Attention Deficit Hyperactivity Disorder Drug Market Research and Analysis by Distribution Channel

The Report Covers

  • Comprehensive research methodology of the global attention deficit hyperactivity disorder drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global attention deficit hyperactivity disorder drug market.
  • Insights about market determinants that are stimulating the global attention deficit hyperactivity disorder drug market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Market Determinants

  • 3.1. Motivators
  • 3.2. Restraints
  • 3.3. Opportunities

4. Market Segmentation

  • 4.1. Global Attention Deficit Hyperactivity Disorder Drug Market by Drug Type
    • 4.1.1. Stimulants
    • 4.1.2. Non-Stimulants
  • 4.2. Global Attention Deficit Hyperactivity Disorder Drug Market by Age Group
    • 4.2.1. Children
    • 4.2.2. Adults
  • 4.3. Global Attention Deficit Hyperactivity Disorder Drug Market by Distribution Channel
    • 4.3.1. Hospital Pharmacies
    • 4.3.2. Retail Pharmacies
    • 4.3.3. E-Commerce

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Eli Lily & Company
  • 6.2. Johnson & Johnson Services, LLC
  • 6.3. Lupin Ltd.
  • 6.4. Mallinckrodt
  • 6.5. NEOS Therapeutics Inc.
  • 6.6. Novartis AG
  • 6.7. Pfizer Inc.
  • 6.8. Prude Pharma L.P.
  • 6.9. Shire